| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2010: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2009: ¥2,860,000 (Direct Cost: ¥2,200,000、Indirect Cost: ¥660,000)
|
|---|
| Research Abstract |
In this study, we used the novel DNA methyltransferase inhibitor zebularine (Zeb) to investigate epigenetic influences on the secretion of VEGF-A in the OSCC cell line HSC-3. Our study revealed that neither the PI3K/Akt nor the p53 signaling pathway is required for Zeb-induced hypoxia-inducible factor-1α (HIF-1α) degradation.
In addition, we investigated the effects of EGFR antagonist Cetuximab on apoptosis induced by anti-cancer drug(5-FU or CDDP )in HSC-3 cells. In this study, we found that Cetuximab significantly enhanced the apoptosis of HSC-3 or HSC-4 cells treated by 5-FU, but not CDDP. These results suggested the mechanism depends on the PI3K/Akt signaling pathway.
|
